Skip to content

プレスリリース

Illumina to Open Latin America Office

SAN DIEGO, Jan 18, 2011 (BUSINESS WIRE) -- Illumina, Inc. (NASDAQ:ILMN) announced today at the 19th Plant and Animal Genome Conference that the company will open an office in Sao Paolo, Brazil, to focus on developing business opportunities across Latin America. The office will open on February 1, 2011.

"We're excited about the potential for expanding our business in Latin America, where Illumina's technology is already facilitating important genetic research in both agriculture and human health," said Matt Posard, Vice President of Global Sales at Illumina. "This new office will strengthen our commitment to the region by making it easier for researchers to access our innovative technology and proven expertise."

For more information, please contact Roberto Braga, General Manager, Latin America Operations, Illumina, at rbraga@illumina.com.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

SOURCE: Illumina, Inc.

Illumina, Inc.
Investors:
Peter J. Fromen
Sr. Director, Investor Relations
858-202-4507
pfromen@illumina.com
or
Media:
Wilson Grabill
Sr. Manager, Public Relations
858-882-6822
wgrabill@illumina.com

Recent Articles

Project Baby Bear – California Pilots Public Health Coverage for WGS
Project Baby Bear – California Pilots Public Health Coverage for WGS
Knowledge is Power: Unlocking the Potential of the Genome
Knowledge is Power: Unlocking the Potential of the Genome
Illumina Accelerator Invests in Four Startups for Ninth Cycle
Illumina Accelerator Invests in Four Startups for Ninth Cycle